Evidence map›Paper›PMID 36599404›Full record

ArticleThe Journal of infection2023

Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in SARS-CoV-2 experienced versus naïve individuals in the general population.

Jorge Camacho, Joao Zulaica, Estela Giménez, Luciana Rusu, Sebastian Velandia-Álvarez, Eliseo Albert, Salvador Peiró, Hermelinda Vanaclocha, Ramón Limón, Ron Geller and 2 more

Open access · bronzeAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Jorge CamachoMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Joao ZulaicaInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980 Valencia, Spain.
Estela GiménezMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Luciana RusuInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980 Valencia, Spain.
Sebastian Velandia-ÁlvarezInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980 Valencia, Spain.
Eliseo AlbertMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Salvador PeiróFoundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain.
Hermelinda VanaclochaGeneral Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.
Ramón LimónGeneral Directorate of Healthcare. Department of Health, Valencian Government, Valencia, Spain.
Ron GellerInstitute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980 Valencia, Spain.
David NavarroMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain. Electronic address: david.navarro@uv.es.
Valencian Vaccine Research Program (ProVaVac) study group
Universitat de València · ESGeneralitat Valenciana · ESINCLIVA Health Research Institute · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansVaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCovid-19COVID-19 vaccinesNeutralizing antibodiesOmicron BA.4/5SARS-CoV-2

Identifiers

PMID36599404
PMCPMC9805797
OpenAlexW4313443210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.